Oragenics Inc. (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants, following the activation of Royal Adelaide Hospital. The company noted that no serious adverse events have been reported in dosed participants to date, and it continues to target a Phase IIa data readout in the fourth quarter of 2026.
In addition to the trial progress, Oragenics submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company stated that the meeting supports its goal of submitting an Investigational New Drug application in the fourth quarter of 2026. This step is critical for advancing the candidate toward potential approval in the United States, where traumatic brain injury affects millions annually.
ONP-002 is a potential first-in-class treatment for concussion and mild traumatic brain injury, delivered via Oragenics' proprietary intranasal delivery technology. The company believes this platform has broad applications across neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. The activation of all Australian trial sites marks a significant milestone in generating clinical data to support further development.
The news underscores Oragenics' commitment to addressing significant unmet medical needs in neurological care. With no serious adverse events observed thus far, the safety profile appears promising. The upcoming FDA meeting will be pivotal in shaping the U.S. clinical pathway, potentially accelerating the timeline for a therapy that could benefit patients worldwide.
